Trump touts completion of first round of White House drug pricing deals with Regeneron

President Trump announced that a pricing agreement with Regeneron marks the final deal of an initial slate of 17 sought by the administration. Under the private arrangement, Regeneron will lower Medicaid prices, sell its cholesterol drug Praluent on the TrumpRx platform for $225, and commit $27 billion to U.S. drug development.

The same day the company disclosed that the FDA approved Otarmeni, a gene therapy for a rare hearing loss, under the agency’s National Priority Voucher program. Early trial data showed modest hearing improvement, and Regeneron said the therapy will be provided at no cost to American patients.

Critics note that the overall impact of the pricing deals may not meet the president’s broader promises, and some members of the Deaf community have expressed concerns about the gene‑therapy approach.